Abstract

Purpose

To assess the feasibility, efficacy, and safety of ultrasound (US)-guided microwave ablation (MWA) for the treatment of papillary thyroid cancer (PTC) located in the thyroid isthmus.

Materials and methods

Thirty-four patients (mean age, 43 ± 11 years; 26 women) with isthmic PTC treated with MWA between June 2014 and September 2020 were included in this retrospective study. The follow-up time after MWA was 17 ± 9 months (range, 8–50 months). Changes in thyroid function, parathyroid function, and tumor size were evaluated, along with the rates of tumor disappearance and complications.

Results

The treatment was technically feasible and successfully completed in all 34 patients (100%). Measures of thyroid function (i.e. serum triiodothyronine, free thyroxine, and thyrotropin) and parathyroid function (i.e. serum calcium and intact parathyroid hormone) showed no changes from pretreatment levels at 1, 3, and 6 months after MWA (p > 0.05 for all). Tumor size was found to be increased at 1 and 3 months after MWA compared with before MWA (p < 0.05). However, the tumor sizes measured at 6, 9, 12, and 18 months after MWA were smaller than the pretreatment sizes (p < 0.05 for all). In 24 cases (70.6%), the tumors completely disappeared on US examination. Five cases (2.9%) experienced side effects from MWA treatment, but no major or minor complications were recorded.

Conclusion

The results of this study demonstrate that US-guided MWA is a feasible, effective, and safe treatment option for selected patients with PTC located in the thyroid isthmus.

中文翻译：

---

微波消融术治疗甲状腺峡部乳头状甲状腺癌的初步研究

摘要

目的

评估超声（美国）引导微波消融（ MWA）治疗位于甲状腺峡部的乳头状甲状腺癌（PTC）的可行性，有效性和安全性。

材料和方法

这项回顾性研究纳入了2014年6月至2020年9月之间接受MWA治疗的PTC峡部PTC患者34例（平均年龄，43±11岁； 26名女性）。MWA后的随访时间为17±9个月（范围8–50个月）。评估甲状腺功能，甲状旁腺功能和肿瘤大小的变化，以及肿瘤消失和并发症的发生率。

结果

该治疗在技术上是可行的，并在所有34例患者中成功完成（100％）。甲状腺功能（即血清三碘甲状腺素，游离甲状腺素和促甲状腺激素）和甲状旁腺功能（即血清钙和完整的甲状旁腺激素）的测量结果显示，MWA后1、3和6个月的治疗前水平没有变化（ 所有p > 0.05） 。发现MWA后1和3个月的肿瘤大小比MWA前增加（p  <0.05）。然而，在MWA后6、9、12和18个月测得的肿瘤大小小于治疗前的大小（p 均<0.05）。在US检查中，有24例（70.6％）肿瘤完全消失。五例（2.9％）因MWA治疗而出现副作用，但未记录到主要或次要并发症。

结论

这项研究的结果表明，对于部分位于甲状腺峡部的PTC患者，美国指导的MWA是一种可行，有效和安全的治疗选择。